Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T-DM1

- PMLiVE

Rival Novartis, Merck drugs square up on rare lung cancer at ASCO

An inflection point for MET-inhibitor class

Roche Basel Switzerland

Roche/GE’s digital medicine alliance bears first fruit

While new player enters liquid biopsy market

Novartis day

FDA clears Novartis’ new breast cancer drug Piqray

Blockbuster potential for PI3K drug

- PMLiVE

So far so good for Amgen’s much-anticipated KRAS inhibitor

Promise to hit previously 'undruggable' target

- PMLiVE

Genentech forges $800m autoimmune alliance with Parvus

Big vote of confidence in novel platform

- PMLiVE

Roche and NHS England hail pricing deal on MS drug Ocrevus

Another pricing deal on high cost medicine

- PMLiVE

AZ invests more in IO with Transgene oncolytic virus deal

Opportunity for combinations with IO pipeline

- PMLiVE

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme

Roche Basel Switzerland

Hemlibra off to a flyer as Roche raises 2019 forecasts

Drug has made almost as much in this quarter as it did in 2018

- PMLiVE

NICE says no to Novartis’ Kisqali combo in breast cancer

Double blow after Lilly rival recommended

- PMLiVE

Lynparza set for further expansion with EU approval in breast cancer

Companies have prostate cancer and pancreatic cancer in their sights

Roche Basel Switzerland

Roche says ‘discovery proteomics’ is heading for clinical trials

Tech has potential to identify novel biomarkers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links